| Company type | Subsidiary |
|---|---|
| Nasdaq: BIVV | |
| Industry | Biotechnology |
| Founded | 2016; 10 years ago (2016) (Spun off fromBiogen) |
Key people | John G. Cox (CEO) [1] |
| Products | Alprolix, Eloctate |
Number of employees | 400[2] |
| Parent | Sanofi |
| Website | sanofi |
Bioverativ Inc. is an Americanmultinationalbiotechnology company that specializes in the discovery, development, and delivery of therapies for the treatment ofhaemophilia.[3] Bioverativ competes withBaxalta (acquired byShire Plc in 2016[4]),Pfizer andNovo Nordisk.[2] The company traded on the NASDAQ exchange under the ticker symbol BIVV untilSanofi completed its acquisition on March 8, 2018.
In May 2016Biogen announced that it wouldspin off its hemophilia drug business (Eloctate and Alprolix) into a separate public company.[5] In August, Biogen announced they would call the spun off companyBioverativ to show heritage with Biogen,[6] and would be spun off in early 2017.[7] On December 22, theSecurities and Exchange Commission approved Bioverativ's registration statement, with the official separation date of the two companies being pegged at February 2017.[8] In February, Biogen investors received a special dividend of one share of Bioverativ stock for every two shares of Biogen stock held as of January 17.[9] Bioverativ began trading on January 12, 2017.[10]
In May 2017, the company announced it would acquireTrue North Therapeutics for $825 million, strengthening Bioverativ's pipeline with the acquisition of TNT009 – a treatment forcold agglutinin disease.[11]
In January 2018,Sanofi announced that it would acquire the business, for $11.6 billion.[3][12]
The following is an illustration of the company's major mergers and acquisitions and historical predecessors:
| Bioverativ |
| |||||||||
The company has two current products;Alprolix andEloctate, both products provided combined revenues of $604 million in 2015, and $640 million in the first nine months of 2016 (contributing to ~6% of Biogens' total revenue.[10] These products are marketed in the United States, European Union, Japan, Canada and Australia.[3]